Adaptimmune Therapeutics (ADAPY)
OTHER OTC:ADAPY
Want to see ADAPY full AI Analyst Report?
ADAPY Stock Chart & Stats
$0.03
-$0.04(-6.19%)
At close: 4:00 PM EST
$0.03
-$0.04(-6.19%)
Day’s Range― - ―
52-Week Range<$0.01 - $0.36
Previous CloseN/A
VolumeN/A
Average Volume (3M)50.65M
Market Cap
$8.35M
Enterprise Value$24.24M
Total Cash (Recent Filing)$26.06M
Total Debt (Recent Filing)$48.68M
Price to Earnings (P/E)―
Beta-7.30
Next Earnings
Aug 12, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.67
Shares Outstanding265,051,600
10 Day Avg. Volume4,539,686
30 Day Avg. Volume50,649,310
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)11.47
Price to Sales (P/S)0.76
P/FCF Ratio-1.79
Enterprise Value/Market Cap2.90
Enterprise Value/Revenue0.37
Enterprise Value/Gross Profit0.39
Enterprise Value/Ebitda-0.16
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.5
Revenue Forecast (FY)$20.70M
Bulls Say, Bears Say
Bulls Say
Asset SaleAdaptimmune has agreed to sell key cell therapies to US WorldMeds for up to $85M, including a $55M upfront payment.
Expansion Of Treatment CentersThe company reported 16 invoiced patients in 2Q, and 30 authorized treatment centers now accepting referrals.
Revenue GrowthTecelra net product revenue for 2Q25 was $11.1M, above consensus estimate and grew ~178% from 1Q25.
Bears Say
Preclinical AssetsThe sale of key assets leaves the company with preclinical assets that are still in the early stages of development.
Stock DowngradeAdaptimmune's stock rating has been downgraded to Neutral from Buy due to the absence of significant near-term opportunities.
Workforce ReductionThe company announced plans to reduce its workforce by 62% as well as the departure of several C-suite executives.
Adaptimmune Therapeutics News
ADAPY FAQ
What was Adaptimmune Therapeutics’s price range in the past 12 months?
Adaptimmune Therapeutics lowest stock price was <$0.01 and its highest was $0.36 in the past 12 months.
What is Adaptimmune Therapeutics’s market cap?
Adaptimmune Therapeutics’s market cap is $8.35M.
When is Adaptimmune Therapeutics’s upcoming earnings report date?
Adaptimmune Therapeutics’s upcoming earnings report date is Aug 12, 2026 which is in 57 days.
How were Adaptimmune Therapeutics’s earnings last quarter?
Currently, no data Available
Is Adaptimmune Therapeutics overvalued?
According to Wall Street analysts Adaptimmune Therapeutics’s price is currently Overvalued.
Does Adaptimmune Therapeutics pay dividends?
Adaptimmune Therapeutics does not currently pay dividends.
What is Adaptimmune Therapeutics’s EPS estimate?
Adaptimmune Therapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Adaptimmune Therapeutics have?
Adaptimmune Therapeutics has 265,051,600 shares outstanding.
What happened to Adaptimmune Therapeutics’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Adaptimmune Therapeutics?
Currently, no hedge funds are holding shares in ADAPY
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Adaptimmune Therapeutics
Adaptimmune Therapeutics plc is a commercial-stage biopharmaceutical company specializing in innovative cell therapies for cancer patients, primarily operating in the United States and the United Kingdom. Its pipeline includes TECELRA (also known as famitresgene autoleucel or afami-cel), an autologous T-cell immunotherapy that employs genetically modified cells to treat adults with advanced, unresectable, or metastatic synovial sarcoma. The company is also advancing Lete-cel for synovial sarcoma and myxoid liposarcoma, and ADP-5701, currently in Phase 1 clinical trials for head and neck cancer. Additionally, Adaptimmune is developing T-cell therapies engineered to target PRAME (ADP-600) and CD70 (ADP-520). The firm engages in strategic collaborations, notably with Galapagos for a clinical proof-of-concept trial of uza-cel (ADP-5701) in head and neck cancer, leveraging Galapagos' decentralized manufacturing platform. Further partnerships include a licensing agreement with Noile-Immune Biotech, Inc. and a strategic alliance with the MD Anderson Cancer Center. Established in 2008, Adaptimmune Therapeutics plc is headquartered in Abingdon, United Kingdom.
Technical Analysis
Ownership Overview
38.24% Insiders
0.05% Mutual Funds
0.18% Other Institutional Investors
61.53% Public Companies and
Individual Investors